Decision-making for Precision Oncology in Advanced Prostate Cancer

This study is for veterans with advanced prostate cancer (cancer that has spread). It aims to understand and improve how patients make decisions about precision oncology. Precision oncology uses genetic and tumor tests to guide cancer treatment. The study will use online surveys and a mobile app to help patients make informed choices. Researchers want to see if these tools can reduce decisional conflict, which is when you feel unsure about a medical decision. You might be able to join if you are 18 or older, can understand English, and are able to complete study procedures. The study plans to enroll 250 participants, but its current status is unclear.

Study design
This interventional study aims to enroll 250 participants. It is not specified if it is randomized or blinded.
What's involved
You would complete online surveys after appointments and use a mobile application on your device. The study may last up to 3 years.
Compensation
Not stated in the trial record.
Follow-up
Your decisional conflict will be measured at 6 months. Enrollment will be tracked for up to 3 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05396872

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer

Recruiting
NAAges 18+InterventionalHealth services
University of California, San Francisco
~250 participants
Updated 2026-03-09 on ClinicalTrials.gov
What's tested:Participant SurveysMobile app

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Mean score on the Decisional Conflict Scale (DCS) (Stage 1)
Measured over 6 months
+3 more outcomes measured
Prostate Cancer
Advanced Prostate Carcinoma
1 sites across 1 states
California1
  • Daniel Kwon, MD · PRINCIPAL_INVESTIGATOR · University of California, San Francisco
UCSF Genitourinary Medical Oncology Recruitment
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Physician specializing in medical oncology (MD, post-first year clinical fellows allowed) who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 30 days of being contacted for this study.
Physician specializing in genetics who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 90 days of being contacted for this study.
Principal investigator of a Precision Oncology Program for Cancer of the Prostate (POPCaP) site.
Physician specializing in medical oncology who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 30 days of being contacted for this study.
Physician specializing in genetics who has discussed genetic testing or targeted therapy with a patient with advanced prostate cancer within the past 90 days of being contacted for this study.
  • Mean score on the Decisional Conflict Scale (DCS) (Stage 1)6 months

    The Decisional Conflict Scale measures personal perceptions of : a) uncertainty in choosing options; b) modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making; and c) effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. Scoring and interpretation Items are given a score value ranging from 0 = 'strongly disagree' to 4 = 'strongly agree'. Total Scores are a sum of the scores of the 16 items and are scaled by divided by 16 and then multiplied by 25 for a total scale score range from 0 \[extremely high decisional conflict\] to 100 \[no decisional conflict\]. Mean score and 95% confidence interval (CI) of the total DCS as well as the 4 subscales will be calculated.

  • Proportion of participants with a total score of >37.5 on the DCS (Stage 1)6 months

    Participants who completed the DCS will be divided by their total score into those who scored \>37.5 or not. The proportion of participants with a total score of \> 37.5 will be reported.

  • Proportion of participants enrolled (Stage 3)Up to 3 years

    The proportion of invited participants who consent to the study compared to the total number of participants approached will be reported as measured by study entry.

  • Proportion of participants providing reason for not enrolling (Stage 3)Up to 3 years

    The proportion of invited participants who do not consent to the study will have the reason for not joining recorded and totaled.